Technical Meeting

Preliminary Meeting Objectives

• Key Considerations for accelerating elimination of HPV-related cancer strategies:
• Analyze the current status of WHO Elimination Goals on a global scale and identify opportunities for acceleration of cervical cancer prevention.
• Present and discuss strategies to accomplish the goal of acceleration of prevention of cancer caused by HPV, such as HPV FASTER and HPV EVEN FASTER.
• Identify research methodologies to gather evidence on HPV transmission prevention.
• Feasibility and cost-effectiveness of cancer prevention acceleration strategies
• Identify essential factors for countries to consider when adopting cervical cancer accelerated elimination, such as cervical cancer screening coverage, screening platforms, vaccination strategies, and epidemiological data for program customization.
• Define the optimal maximum age for HPV vaccination and related determinants.
• Explore the utility of modeling studies in refining and advancing these programs.
• Analyze the influence of vaccine pricing, dosing, and scheduling on cervical cancer accelerated elimination cost-effectiveness, and propose optimization strategies.
• Evaluation of accelerated cervical cancer elimination strategies
• Discuss methods to measure both the goal indicators and cost-effectiveness of HPV FASTER initiatives.
• Deliberate on specific resource-stratified requirements at the country level for implementation of HPV FASTER.
• Assessment of HPV FASTER Implementation Across Countries
• Review the needs assessment procedures that led to the adoption of HPV FASTER in different countries, highlighting lessons learned and best practices.
• Understand the next steps and future research needs/gaps for these strategies

DAY 1 - Thursday, June 6, 2024

SESSION 1: WELCOME AND INTRODUCTION

Welcome and Introduction

Alex Vorsters (University of Antwerp) (Video, Pdf)

SESSION 2: UPDATE ON WHO'S CERVICAL CANCER ELIMINATION GOALS
Chairs: Paolo Bonanni (University of Florence) & Narendra K. Arora (The INCLEN Trust)​​​

• WHO Cervical Cancer Elimination Goals – increasing access to cervical cancer screening and treatment
  Maribel Almonte (IARC) (Video, Pdf)
• Global overview on the status of cervical cancer screening
  Marc Arbyn (Sciensano) (Video)
• Current landscape of HPV vaccination and the way towards elimination
  Paul Bloem (WHO) (Video, Pdf)
• Q&A (Video)

SESSION 3: INSIGHTS INTO HPV NATURAL INFECTION AND TRANSMISSION DYNAMICS 
Chairs: Mario Poljak (University of Ljubljana) & Susanne Krüger Kjær (Danish Cancer Institute)

• Research insights on latency, immune control and subclinical infection.
  John Doorbar (UC) – Basic science (Video, Pdf)
  Patti Gravitt (NIH) – Clinical evidence (Video, Pdf)
• Q&A (Video)
• Understanding local HPV-related immunity using First Void Urine (FVU)
  Laura Téblick (UA) (Video, Pdf)
• HPV vaccination on HPV-positive women: Using functional in-vitro models to understand HPV infectivity and transmission
  Miguel Ángel Pavón (ICO) (Video, Pdf)
• Investigations to understand HPV transmission among heterosexual couples: TRAP-HPV trial & HITCH cohort study
  Eduardo Franco (McGill University) (Video, Pdf)
• Adjuvant effect of HPV vaccine on recurrent respiratory papillomatosis
  Shazia Peer (University of Cape Town) (Video)
• Q&A and Discussion
  - What gaps exist in our understanding of HPV infection, and what additional information is necessary to fill these gaps?
  - How are we monitoring HPV infections?
  (Video)

SESSION 4: IMPLEMENTATION OF HPV FASTER: LESSONS LEARNED, FEASIBILITY AND COST-EFFECTIVENESS
Chairs: Rolando Herrero (ACIB) & Sharon Hanley (University of Aberdeen)

• An overview on HPV Faster: Understanding the concept of HPV Faster and the way forward
  Xavier Bosch (ICO) (Video)
• Targeting FASTER to reduce HPV reproductive rates: “Even Faster”
  Joakim Dillner (Karolinska Institutet) (Video, Pdf)
• HPV Faster implementation in Mexico: A pilot study
  Jorge Salmerón - MoH, Mexico (Video, Pdf)
• Enhancing HPV elimination efforts in Israel
  Jacob Bornstein (ISSSTI, Israel) (Video, Pdf)
• Accelerating HPV related cancer elimination: Bhutan’s Cervical Cancer Elimination Flagship program (as an example from LMIC)
  Pempa Pempa (MoH, Bhutan) (Video, Pdf)
• Q&A (Video)

SESSION 5: PANEL/ROUND TABLE DISCUSSION: HPV FASTER FEASIBILITY AND EQUITY
Chairs: Aimee Kreimer (NIH) & Kate Cuschieri (University of Edinburgh)

• Research and implementation opportunities to accelerate cervical cancer prevention in Costa Rica
  Aimee Kreimer (NIH) (Video, Pdf)
• Topic: HPV FASTER – Feasibility & Equity
  - Can current evidence support a nested HPV vaccination program/campaign in cervical cancer screening?
  - Context-specific implementation feasibility considerations: vaccine dosage, supply prioritization, cervical screening platform, structure, etc.
  - Should HPV FASTER be deployed through campaigns or integrated into routine healthcare settings for optimal impact?
  - How can HPV FASTER be implemented to promote equity in eliminating cervical cancer and other HPV-related diseases? What are the equity considerations and risks?
  
  Panelists: Joakim Dillner (online), Marc Arbyn, Iacopo Baussano, Maribel Almonte, Ruanne Barnabas (online), Marc Bardou
  (Video)

DAG 2 - Friday, June 7, 2024

DAY 2: WELCOME SESSION
Chairs: Alex Vorsters (University of Antwerp)

Welcome and Brief overview of day 1 discussions
Alex Vorsters (Video)

SESSION 6: ACCELERATING ELIMINATION OF CERVICAL CANCER: TRANSFORMING CURRENT INSIGHTS INTO EQUITABLE STRATEGIES FOR GLOBAL SUCCESS
Chairs: Dorothy Machalek (Kirby Institute) & Eduardo Franco (McGill University)

• ​​Rethinking Cervical Cancer Elimination Goal Indicators: From ASR to Lifetime risks
  Eduardo Franco (McGill University) (Video, Pdf)
• Effective HPV vaccine dose reallocation given recent single dose recommendation & increased supply and manufacturers
  Irene Man (IARC) (Video, Pdf)
• Optimal HPV vaccination strategies in LMICS to reach cervical cancer elimination
  Marc Brisson (Université Laval) (Video)
• Q&A (Video)
• Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes
  Marc Brisson (Université Laval) (Video)
• Impact of catch-up human papillomavirus vaccination on cervical cancer incidence in Kenya: A mathematical modelling evaluation of HPV vaccination strategies in the context of moderate HIV prevalence
  Ruanne Barnabas – pre-recorded (Harvard University) (Video, Pdf)
• Q&A (Video)

SESSION 7: HPV FASTER STRATEGY FOR AT-RISK POPULATION AND STRATEGIES TO MOVE FORWARD
Chairs: Marc Steben (ISTTDR) & Armando Baena (IARC)​​

• Considerations of HPV Faster strategy in at-risk populations
  Marc Bardou (INSERM) (Video, Pdf)
• Overview on IARC’s projects targeting at-risk population
  Iacopo Baussano (IARC) (Video, Pdf)
• Q&A (Video)

SESSION 8: BREAKOUT GROUPS
Chairs: TBD​

• Breakout groups
  Breakout Group 1:
  Chairs:
  Breakout Group 2:
  Chairs:
  Breakout Group 3:
  Chairs:
• Plenary Feedback
  (Video)

SESSION 9: CONCLUSION
Chairs: TBD

• ​Summary
  Marc Baay (Video, Pdf)
• Concluding remarks
  Alex Vorsters (Video)